title: [Clinical-encephalographic evaluation of preterm children treated with cytoflavin during the first year of life].
abstract: An aim of the study was the clinical and neurophysiological evaluation of the effect of cytoflavin and reanimation measures on the rate of nervous and mental development of preterm newborns with cerebral ischemia, II--III stage, during the first year of life. One hundred and twenty children with gestational age 28--36 weeks and body mass 1060-3150 g were studied. In the main group (n=61), the complex treatment included cytoflavin in dosage 2 ml/kg/day, intravenously during 5 days. The control group (n=59) received basic treatment without cytoflavin. The follow-up till the age of 1 year comprised the global assessment of state and neurological status using quantitative measurements of muscle postural tone on the INFANIB scale, psychomotor development (BSID-II) and assessment of CNS functional state by analyzing computed EEG signals during physiological sleep. The results obtained demonstrated the fast normalization of all studied measures of development of children treated with cytoflavin compared to those of the control group.
authors.forename: S O
authors.initials: SO
authors.lastname: Rogatkina
authors.forename: M G
authors.initials: MG
authors.lastname: Degtiareva
authors.forename: O V
authors.initials: OV
authors.lastname: Grebennikova
authors.forename: N N
authors.initials: NN
authors.lastname: Volodin
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Sigova
authors.forename: G A
authors.initials: GA
authors.lastname: Asmolova
authors.forename: N D
authors.initials: ND
authors.lastname: Serova
mesh_terms: D002657:Child Development / Q000187:drug effects* / Q000502:physiology; D004338:Drug Combinations; D004569:Electroencephalography; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000254:growth & development*; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D015931:Intensive Care, Neonatal; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D011596:Psychomotor Disorders / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate